Physician profile
Kyle William Binder
NPI 1841635422
$5,762.52
in general payments reported to CMS, 2019-2025
49 companies · $28.57 in 2025
The $28.57 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $313 · 2021: $1,590 · 2022: $2,438 · 2023: $1,305 · 2024: $88.64 · 2025: $28.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,164.65 | 2021-2023 | Ubrelvy, Qulipta, Botox |
| Lilly USA, LLC | $411.11 | 2020-2023 | Emgality, Reyvow, Amyvid |
| Biogen, INC. | $284.01 | 2020-2023 | Vumerity, Tysabri, Avonex |
| Teva Pharmaceuticals USA, INC. | $243.99 | 2020-2025 | Austedo, Ajovy |
| Celgene Corporation | $240.31 | 2021-2023 | Zeposia |
| Novartis Pharmaceuticals Corporation | $235.76 | 2022-2023 | |
| Genzyme Corporation | $220.42 | 2021-2023 | |
| Eisai INC. | $200.00 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $194.84 | 2020-2023 | Soliris |
| Janssen Pharmaceuticals, INC | $187.80 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $180.64 | 2021-2024 | Ingrezza, Ongentys |
| Ucb, INC. | $177.35 | 2022-2023 | Briviact |
| Emd Serono, INC. | $163.78 | 2022-2023 | Mavenclad |
| Biohaven Pharmaceuticals, INC. | $144.58 | 2021 | |
| Genentech USA, INC. | $143.23 | 2021-2023 | Ocrevus |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Binder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.